Cambridge, MA According to BioMed Realty Trust, Inc., Seres Therapeutics, a leading microbiome therapeutics platform company, has signed a lease for 83,000 s/f at Biomed Realty’s 200 Sidney St. property, bringing the building to 100% leased. As the building’s largest tenant, Seres will relocate its new corporate headquarters in three phases starting in the first quarter of 2016, with each of the leases expiring in November 2023. Seres joins fellow life science innovators at 200 Sidney St., including AbbVie, CRISPR Therapeutics, RaNA Therapeutics and Synlogic.

The move to BioMed Realty’s 200 Sidney St. building, an integral part of Cambridge’s “Research Row,” allows Seres to unite its fast-growing company under one roof, including research and development, pilot-scale manufacturing, corporate, regulatory and commercial activities. The phased move is expected to begin in spring 2016, starting with office and lab functions, and continue through the summer.

“We are excited about Seres Therapeutics’ entry into the Cambridgeport life science market and look forward to welcoming them in our newly redeveloped 200 Sidney St. building,” said Morgan Weinstein, senior director of BioMed Realty. “Premier life science companies like Seres recognize the value of our strategic investment in the building’s infrastructure, which allows for future program flexibility, as well as providing an amenity-rich environment. We look forward to supporting Seres’ research, clinical studies and commercialization efforts at the Sidney Research Campus for many years to come.”

Having recently completed a $140 million initial public offering, Seres required additional space to support its fast growth as the leading microbiome therapeutics platform company.

Relocating to 200 Sidney St. allows Seres to continue its expansion in the vibrant Cambridge community among other leading companies and academics, with abundant opportunities for collaboration within Sidney Research Center.

The 200 Sidney St. property is part of BioMed Realty’s Sidney Research Campus, which comprises approximately 338,000 s/f of class A laboratory and office space across three buildings. The building was previously one of three properties occupied by Vertex Pharmaceuticals, which BioMed recaptured earlier this year and began to immediately reposition to meet the growing demand for lab space from life science companies in the thriving Cambridge market. At 200 Sidney St., Seres will be able to reutilize the existing lab’s infrastructure for its evolving needs.

Currently, BioMed Realty owns more than three million s/f of laboratory and office space in the Boston/Cambridge market.

BioMed Realty, with its trusted expertise and valuable relationships, delivers optimal real estate solutions for biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty owns or has interests in properties comprising 18.9 million rentable s/f.